The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer

Lopez‐Pastorini, Alberto; Riedel, Richard; Koryllos, Aris; Beckers, Frank; Ludwig, Corinna; Stoelben, Erich

doi:10.1016/j.lungcan.2017.05.003

Cited by 14 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During tumor progression, this crosstalk may generate more aggressive tumors. In fact, previous clinical studies reported that an elevated CRP level was a poor prognostic factor in NSCLC patients (33,34).…”

Section: Discussionmentioning

confidence: 98%

M2 tumor‑associated macrophages promote tumor progression in non‑small‑cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Tumor-associated macrophages (TAMs) are key components of the tumor microenvironment that can be polarized into different phenotypes, including tumor-inhibiting M1 macrophages and tumor-promoting M2 macrophages. To elucidate the biological and clinical significance of M2 TAMs in non-small-cell lung cancer (NSCLC), a comprehensive clinical assessment of the tissue distribution of M2 TAMs was performed. The tissue distribution of M2 TAMs was retrospectively analyzed using CD163 immunohistochemistry in 160 consecutive patients who underwent NSCLC resection. Tumor proliferation was evaluated via the Ki-67 proliferation index. The results revealed that the stromal density of M2 TAMs was significantly associated with the C-reactive protein (CRP) level (P=0.0250), the Ki-67 proliferation index (P=0.0090) and invasive size (P=0.0285). Furthermore, the stromal M2 TAM density was significantly associated with tumor differentiation (P=0.0018), lymph node metastasis (P=0.0347) and pathological stage (P=0.0412). The alveolar M2 TAM density was also significantly associated with the CRP level (P= 0.0309), invasive size (P<0.0001), tumor differentiation (P=0.0192), tumor status (P=0.0108) and pathological stage (P=0.0110). By contrast, no association was observed between islet M2 TAM density and the aforementioned biological and clinical factors. In regards to prognosis, disease-free survival rate was significantly lower in patients with stromal M2 TAM-high tumors (P=0.0270) and in those with alveolar M2 TAM-high tumors (P=0.0283). Furthermore, the overall survival rate was also significantly lower in patients with stromal M2 TAM-high tumors (P=0.0162) and in those with alveolar M2 TAM-high tumors (P=0.0225). Therefore, during NSCLC progression, M2 TAMs may induce tumor cell aggressiveness and proliferation and increase metastatic potential, resulting in a poor prognosis in patients with NSCLC.

show abstract

Section: Discussionmentioning

confidence: 98%

M2 tumor‑associated macrophages promote tumor progression in non‑small‑cell lung cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Lung cancer (LC) is one of the most malignant neoplasms, and increases in its morbidity and mortality rates have made it a main cause of human mortality. In the last 50 years, research has revealed a marked increase in the incidence and mortality rates of LC (1). The incidence and mortality rates of LC in men ranked first among all malignant tumor groups, and the incidence in women ranked second most common worldwide in 2018 (2).…”

Section: Introductionmentioning

confidence: 99%

Identification of differentially expressed genes between primary lung cancer and lymph node metastasis via bioinformatic analysis

Zhang

2019

Oncol Lett

View full text Add to dashboard Cite

Lung cancer (LC), with its high morbidity and mortality rates, is one of the most widespread and malignant neoplasms. Mediastinal lymph node metastasis (MLNM) severely affects postoperative survival of patients with LC. Additionally, the molecular mechanisms of LC with MLNM (MM LC) remain not well understood. To identify the key biomarkers in its carcinogenesis and development, the datasets GSE23822 and GSE13213 were obtained from the Gene Expression Omnibus database. The differentially expressed genes (DEGs) were identified, and the Database for Annotation, Visualization and Integrated Discovery was used to perform functional annotations of DEGs. Search Tool for the Retrieval of Interacting Genes and Cytoscape were utilized to obtain the protein-protein interaction (PPI) network, and to analyze the most significant module. Subsequently, a Kaplan-Meier plotter was used to analyze overall survival (OS). Additionally, one co-expression network of the hub genes was obtained from cBioPortal. A total of 308 DEGs were identified in the two microarray datasets, which were mainly enriched during cellular processes, including the Gene Ontology terms ‘cell’, ‘catalytic activity’, ‘molecular function regulator’, ‘signal transducer activity’ and ‘binding’. The PPI network was composed of 315 edges and 167 nodes. Its significant module had 11 hub genes, and high expression of actin β, MYC, arginine vasopressin, vesicle associated membrane protein 2 and integrin subunit β1, and low expression of NOTCH1, synaptojanin 2 and intersectin 2 were significantly associated with poor OS. In summary, hub genes and DEGs presented in the present study may help identify underlying targets for diagnostic and therapeutic methods for MM LC.

show abstract

“…Tumor progression is suggested to be closely associated with cancer-related inflammatory and nutritional statuses [5][6][7]. Previous studies have identified several inflammation/ nutrition biomarkers as prognostic factors; these include body mass index (BMI) [8,9], C-reactive protein (CRP) [10][11][12], CRP-to-albumin (ALB) ratio (CAR) [13,14], and neutrophilto-lymphocyte ratio (NLR) [15][16][17][18]. Additionally, the advanced lung cancer inflammation index (ALI) at baseline has recently been shown to be an independent predictor of survival in patients with advanced NSCLC [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Shiroyama¹,

Suzuki²,

Tamiya

et al. 2017

Cancer Medicine

View full text Add to dashboard Cite

Programmed death‐ligand 1 (PD‐L1) expression status is inadequate for indicating nivolumab in patients with non–small cell lung cancer (NSCLC). Because the baseline advanced lung cancer inflammation index (ALI) is reportedly associated with patient outcomes, we investigated whether the pretreatment ALI is prognostic in NSCLC patients treated with nivolumab. We retrospectively reviewed the medical records of all patients treated with nivolumab for advanced NSCLC between December 2015 and May 2016 at three Japanese institutes. Multivariate logistic regression and Cox proportional hazards models were used to assess the impact of the pretreatment ALI (and other inflammation‐related parameters) on progression‐free survival (PFS) and early progression (i.e., within 8 weeks after starting nivolumab). A total of 201 patients were analyzed; their median age was 68 years (range, 27–87 years), 67% were men, and 24% had an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher. An ECOG performance status ≥2, serum albumin <3.7 g/dL, neutrophil‐to‐lymphocyte ratio ≥4, and ALI <18 were significantly associated with poor PFS and early progression on univariate analysis. Multivariate analyses revealed that pretreatment ALI <18 was independently associated with inferior PFS (median, 1.4 vs. 3.7 months, P < 0.001) and a higher likelihood of early progression (odds ratio, 2.76; 95% confidence interval 1.44–5.34; P = 0.002). The pretreatment ALI was found to be a significant independent predictor of early progression in patients with advanced NSCLC receiving nivolumab, and may help identify patients likely to benefit from continued nivolumab treatment in routine clinical practice.

show abstract

The impact of preoperative elevated serum C-reactive protein on postoperative morbidity and mortality after anatomic resection for lung cancer

Cited by 14 publications

References 33 publications

M2 tumor‑associated macrophages promote tumor progression in non‑small‑cell lung cancer

M2 tumor‑associated macrophages promote tumor progression in non‑small‑cell lung cancer

Identification of differentially expressed genes between primary lung cancer and lymph node metastasis via bioinformatic analysis

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer

Contact Info

Product

Resources

About